Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis

Authors

Nicholas Lombardi, St. John Fisher University
Anthoula Kritikos, St. John Fisher University
Jacky Ye, St. John Fisher University
Dr. Victor Cohen, St. John Fisher University

Document Type

Poster Presentation

Publication Date

4-25-2025

Keywords

fsc2025

Abstract

Presentation at the annual 2025 ASHP Midyear Clinical Meeting and Exhibition: This project was a medication use evaluation (MUE), intended to determine whether providers at 7 NYC Health + Hospitals facilities met the criteria of the Dalbavancin Standard Plan of Treatment for Sequential Therapy for Infective Endocarditis and Osteomyelitis. This was accomplished through a retrospective inpatient chart review and by determining patient eligibility, proper indication, and appropriate administration. All dalbavancin orders were compiled between October 2022 and May 2024. Additionally, this MUE served to gauge the effectiveness of dalbavancin therapy across NYC Health + Hospitals facilities within this timeframe.

Comments

Student poster presented at the 2025 Fisher Showcase, St. John Fisher University, April 25, 2025.

Publication Information

Lombardi, Nicholas; Kritikos, Anthoula; Ye, Jacky; and Cohen, Dr. Victor, "Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis" (2025). Fisher Showcase 2025. Paper 108.
https://fisherpub.sjf.edu/fsc2025/108

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit https://libguides.sjf.edu/citations.